Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 670318, 6 pages
Research Article

Attitudes toward HPV Vaccination among Women Aged 27 to 45

1Global Health Outcomes, Merck & Co., Inc., P.O. Box 4, WP97-A243, 770 Sumneytown Pike, West Point, PA 19486-0004, USA
2Department of Pediatrics, Columbia University, 3959 Broadway, CHC Central/South 1124, New York, NY 10032, USA
3Department of Pediatrics, Indiana University School of Medicine, West 10th Street, HS 1001, Indianapolis, IN 46202, USA

Received 14 February 2011; Accepted 15 March 2011

Academic Editors: Y. S. Song, C. Tayade, and L. C. Zeferino

Copyright © 2011 Thomas W. Weiss et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The purpose of this study was to identify attitudes toward HPV vaccination among US women 27 to 45 years of age. A survey was mailed to 2,750 insured US women to assess perceptions of relevance or irrelevance of the HPV vaccine, the underlying reasons, and, for those reporting relevance, the likelihood of vaccination if it became available. Among the 451 eligible respondents, 304 (67.4%) reported that the HPV vaccine was relevant to them, whereas 143 (31.7%) stated that it was not at all relevant. The most common reasons for relevance were protection from cervical cancer (62.8%), vaginal cancer (58.2%), precancerous cells (55.9%), HPV (55.6%), and genital warts (46.4%). Reasons for irrelevance were most commonly being married (54.0%) or in a monogamous relationship (39.6%). Most respondents reporting relevance of the HPV vaccine were likely (33.4%) or extremely likely (37.7%) to receive the vaccine if approved for their age group.